NCT05785767: An ongoing trial by Regeneron Pharmaceuticals
This trial is ongoing. It must report results 5 years, 2 months from now.
Full data
| Full entry on ClinicalTrials.gov | NCT05785767 |
|---|---|
| Title | A Randomized, Double-Blind Phase 2/3 Study of Fianlimab (Anti-LAG-3 Antibody) in Combination With Cemiplimab (Anti-PD-1 Antibody) Versus Cemiplimab Monotherapy in First-Line Treatment of Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) With Tumors Expressing PD-L1 ≥50% |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | June 30, 2023 |
| Completion date | March 11, 2030 |
| Required reporting date | March 11, 2031, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | None |